ArticleCombinatorial chemistry & high throughput screening2026
MiR-509-3p Targets YAP1 to Regulate Inflammatory Cytokines Against Hyperglycemia-Induced Renal Tubular Cell Damage in Diabetic Kidney Disease.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionHyperglycemia-induced renal inflammation and the subsequent activation of inflammatory cytokines play critical roles in Diabetic Kidney Disease (DKD) progression. However, the underlying molecular mechanisms, particularly those involving microRNAs, remain poorly understood.
methodsSerum samples from DKD patients (n = 10) and healthy controls (n = 10) were subjected to microRNA transcriptome profiling. An in vitro DKD model was established by treating Human Renal Tubular Epithelial Cells (RTECs and HK-2) with High Glucose (HG). The levels of pro-inflammatory cytokines, Interleukin (IL)-1β, IL-6, and Tumor Necrosis Factor (TNF)-α, were assessed using quantitative reverse transcription-PCR and enzyme-linked immunosorbent assay. Dual-luciferase reporter assays evaluated the relationship between miR-509-3p and Yesassociated protein 1 (YAP1). In situ hybridization and immunohistochemistry were performed to validate the expressions of miR-509-3p and YAP1 in kidney tissues from DKD patients (n = 38) and controls (n = 38).
resultsMiR-509-3p was identified as one of the most significantly dysregulated microRNAs in the serum of DKD patients. Its expression was significantly downregulated in a dose-dependent manner in HG-induced RTECs and HK-2 cells (p <0.01). Overexpression of miR-509-3p significantly suppressed HG-induced pro-inflammatory cytokine expression (p <0.01). Suppression of miR-509-3p further enhanced HG-induced IL-1β, TNF-α, and IL-6 expression, whereas this effect was reversed by silencing YAP1 (p <0.01). Mechanistically, miR-509-3p directly targeted the 3'-UTR of YAP1 mRNA. Consistently, DKD renal tissues exhibited reduced miR-509-3p and elevated YAP1 expression, with a significant negative correlation (p = 0.002). Furthermore, miR-509-3p and YAP1 were significantly correlated with estimated glomerular filtration rate and urine albumin-creatinine ratio (p <0.001).
conclusionThe study preliminarily suggests that miR-509-3p/YAP1 axis may act as a crucial regulator of hyperglycemia-induced tubular inflammation, offering a potential therapeutic target for DKD.
Indexed as
Identifiers
41239928What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.